Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success and recognition in the field [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's management provided misleading information regarding the efficacy of setrusumab (UX 143) in reducing fracture rates in patients with Osteogenesis Imperfecta [5]. - It is claimed that while setrusumab increases bone density, this does not correlate with a decrease in fracture rates, and the studies were less likely to demonstrate the claimed results than management suggested [6]. - The misleading statements allegedly led to investors purchasing shares at inflated prices, resulting in damages when the true information became public [6].

Core Viewpoint - An investigation has been launched into potential breaches of fiduciary duty by the directors, officers, and controlling shareholder of Mister Car Wash, Inc. following its announcement of a merger agreement with Leonard Green & Partners at a price significantly below its recent trading high [1] Company Overview - Mister Car Wash operates approximately 550 locations and claims to have the largest car wash subscription program in North America [1] Acquisition Details - On February 18, 2026, Mister Car Wash announced a definitive merger agreement with investment funds managed by Leonard Green & Partners, offering $7.00 per share, which represents a nearly 20% discount from the company's 52-week high [1] - Leonard Green currently owns about 67% of Mister Car Wash's outstanding shares and has secured the necessary vote for the acquisition through a "Written Consent," eliminating the need for a vote from minority stockholders [1] - If the acquisition is completed, Mister Car Wash's common stock will be delisted from the Nasdaq Global Market and deregistered under the Securities Exchange Act of 1934 [1]

Core View - The article discusses a securities fraud lawsuit against CoreWeave, Inc. (NASDAQ: CRWV) and highlights the opportunity for investors who purchased securities during the class period from March 28, 2025, to December 15, 2025, to lead the lawsuit [1] Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A lead plaintiff must file a motion with the court by March 13, 2026, to represent other class members in the litigation [1] - The lawsuit alleges that CoreWeave made false and misleading statements regarding its ability to meet customer demand and the risks associated with its reliance on a single third-party data center supplier [1] Allegations Against CoreWeave - The defendants allegedly overstated CoreWeave's capacity to meet customer demand [1] - The lawsuit claims that the severity of risks related to the third-party data center supplier was materially understated [1] - It is asserted that these misrepresentations were likely to have a significant negative impact on CoreWeave's revenue [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against NuScale Power Corporation, alleging material misstatements regarding its commercialization strategy for nuclear power generation projects [1] Summary by Relevant Sections Lawsuit Details - The lawsuit is filed on behalf of investors who purchased NuScale Class A common stock between May 13, 2025, and November 6, 2025 [1] - The deadline for investors to seek lead plaintiff status is April 20, 2026 [1] - The case is filed in the United States District Court for the District of Oregon, titled Truedson v. NuScale Power Corporation, et al, Case No. 3:26-cv-00328 (D. Or.) [1] Allegations - The complaint alleges that NuScale made false or misleading statements and failed to disclose that ENTRA1 Energy LLC had no significant experience in building or operating nuclear power projects [1] - It is claimed that NuScale entrusted its commercialization and deployment of its power module to ENTRA1, which lacked relevant experience [1] - The lawsuit also states that the qualifications attributed to ENTRA1 were actually related to the Habboush Group, another entity without significant nuclear experience [1] - As a result, NuScale's commercialization strategy faced undisclosed risks of failure, delays, and regulatory challenges [1] Financial Impact - On November 6, 2025, NuScale reported a significant increase in general and administrative expenses, which rose over 3,000% to $519 million from $17 million in the previous year [1] - This increase was largely due to a $495 million payment to ENTRA1 for a TVA agreement [1] - Consequently, NuScale's quarterly net loss surged to $532 million, compared to $46 million in the prior year [1] - Following this announcement, NuScale's stock price dropped by $5.45 per share, or approximately 14.4%, closing at $32.46 on November 6, 2025 [1] Investor Actions - Investors are advised to retain counsel or contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation [1] - They can also file to be lead plaintiff by the April 20, 2026 deadline [1] - The lead plaintiff will represent the class in directing the litigation and selecting counsel [1]

LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION [Accessibility Statement] Skip NavigationTime-Sensitive: Allegations Focus on Repeated Assurances Regarding Setrusumab EfficacyRARE INVESTOR ALERT"Investors deserve transparency about material risks that could affect their investments," stated Joseph E. Levi, Esq., managing partner of Levi & Korsinsky, LLP. "The adequacy of clinical trial risk disclosures is a fundamental issue for biopharm ...

We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on RARE. Ultragenyx Pharmaceutical Inc.'s share was trading at $23.88 as of February 9th. Zoetis (ZTS) Hits New 52-Week Low on Dismal Outlook M. A. Arkhipov/Shutterstock.com Ultragenyx Pharmaceuticals positions itself as a diversified rare disease company with four approved products generating approximately $670 million in annual ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's management provided misleading information regarding the efficacy of setrusumab (UX 143) in clinical trials for Osteogenesis Imperfecta, leading to inflated stock prices [5][6]. - It is claimed that while setrusumab increased bone density, it did not correlate with a decrease in fracture rates, contrary to management's assertions [6].

Core Viewpoint - PayPal Holdings, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding its revenue outlook and growth potential during the Class Period from February 25, 2025, to February 2, 2026 [1] Group 1: Class Action Lawsuit Details - The lawsuit, Goodman v. PayPal Holdings, Inc., claims that PayPal and certain executives violated the Securities Exchange Act of 1934 [1] - Investors who suffered substantial losses during the Class Period have until April 20, 2026, to seek appointment as lead plaintiff [1] - The lawsuit alleges that PayPal's optimistic growth plans were unrealistic and that the company minimized risks associated with macroeconomic fluctuations [1] Group 2: Financial Performance and Impact - On February 3, 2026, PayPal announced disappointing financial results for Q4 and full fiscal year 2025, including a decline in Branded Checkout performance and the withdrawal of its 2027 financial targets [1] - The announcement led to a more than 20% drop in PayPal's stock price [1] - The company attributed its poor performance to macroeconomic factors, competition, and operational issues across all regions [1] Group 3: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased PayPal common stock during the Class Period to seek lead plaintiff status [1] - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [1] - An investor's potential recovery is not contingent upon serving as lead plaintiff [1] Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 [1] - The firm has a strong track record, recovering $8.4 billion for investors over the past five years [1] - Robbins Geller is one of the largest plaintiffs' firms globally, with a history of significant securities class action recoveries [1]

Core Viewpoint - NuScale Power Corporation is facing a class action lawsuit due to alleged misleading statements regarding its commercialization partnership with ENTRA1 Energy LLC and significant financial losses reported in its recent fiscal quarter [1] Group 1: Class Action Lawsuit Details - Investors who purchased NuScale Class A common stock between May 13, 2025, and November 6, 2025, can seek to be lead plaintiffs in the class action lawsuit by April 20, 2026 [1] - The lawsuit alleges violations of the Securities Exchange Act of 1934 by NuScale, its executives, and Fluor Corporation [1] - The lawsuit claims that NuScale made false statements about ENTRA1's capabilities, which lacked experience in nuclear power generation [1] Group 2: Financial Impact - NuScale's general and administrative expenses surged over 3,000% to $519 million in the third fiscal quarter, up from $17 million in the previous year [1] - The company's quarterly net loss increased to $532 million, compared to $46 million in the prior year [1] - Analysts questioned NuScale's CEO about ENTRA1's qualifications during a conference call, revealing potential milestone payments exceeding $3 billion [1] Group 3: Partnership and Technology - NuScale's core technology, the NuScale Power Module (NPM), is designed for energy generation within a broader power plant [1] - The partnership with ENTRA1 was expected to advance NuScale's technology from development to deployment, validated by a joint agreement with the Tennessee Valley Authority (TVA) for up to six gigawatts of nuclear power [1]

Kyndryl Holdings, Inc. (KD) Class Action Lawsuit Seeks Recovery for Investors; April 13, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP [Accessibility Statement] Skip NavigationDid you buy KD securities between August 7, 2024, and February 9, 2026?Affected Kyndryl Holdings, Inc. Investor Summary- Investor Action: Contact [Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)] for recovery options at no cost to investor- Key Lawsuit Allegations: Material misstatements and/or omissions concerning the ...